DYN vs. MRVI, GERN, ARVN, ARDX, RYTM, PTCT, KROS, DCPH, RCKT, and VERA
Should you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Maravai LifeSciences (MRVI), Geron (GERN), Arvinas (ARVN), Ardelyx (ARDX), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Keros Therapeutics (KROS), Deciphera Pharmaceuticals (DCPH), Rocket Pharmaceuticals (RCKT), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical preparations" industry.
Dyne Therapeutics (NASDAQ:DYN) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Maravai LifeSciences has higher revenue and earnings than Dyne Therapeutics. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
Dyne Therapeutics presently has a consensus price target of $37.75, indicating a potential upside of 31.30%. Maravai LifeSciences has a consensus price target of $11.44, indicating a potential upside of 3.10%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Maravai LifeSciences.
Dyne Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -47.81%. Maravai LifeSciences' return on equity of -4.28% beat Dyne Therapeutics' return on equity.
Maravai LifeSciences received 43 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Dyne Therapeutics an outperform vote while only 67.44% of users gave Maravai LifeSciences an outperform vote.
Dyne Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Maravai LifeSciences has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Maravai LifeSciences had 2 more articles in the media than Dyne Therapeutics. MarketBeat recorded 9 mentions for Maravai LifeSciences and 7 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.97 beat Maravai LifeSciences' score of 0.69 indicating that Dyne Therapeutics is being referred to more favorably in the media.
Summary
Dyne Therapeutics beats Maravai LifeSciences on 10 of the 17 factors compared between the two stocks.
Get Dyne Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyne Therapeutics Competitors List
Related Companies and Tools
